Evercore ISI Cuts Teradata (NYSE:TDC) Price Target to $32.00
Teradata (NYSE:TDC – Free Report) had its target price cut by Evercore ISI from $37.00 to $32.00 in a research report report ...
Vertiv (NYSE:VRT) Given New $131.00 Price Target at Barclays
Vertiv (NYSE:VRT – Get Free Report) had its price target dropped by analysts at Barclays from $142.00 to $131.00 in a research report issued on Thursday,Benzinga reports. The firm currently has an ...
Karman Announces Closing of its Upsized Initial Public Offering, with Full Exercise of Over-Allotment Option
Karman Holdings Inc. ("Karman" or the "Company"), a company specializing in the upfront design, testing, manufacturing, and sale of mission-critical systems for existing and emerging missile and ...
Evercore ISI's Mark Mahaney likes Meta, but says other names will give more upside
Mark Mahaney, Evercore ISI head of internet research, joins 'Closing Bell' to discuss the markets, Meta's historic winning ...
Vera plunges as Otsuka updates on rival therapy
Vera Therapeutics (VERA) stock falls as Otsuka (OTSKF) updates on its IgA nephropathy therapy sibeprenlimab, which rivals ...
CRISPR upped to outperform by Evercore on upcoming data
Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.
Fintel on MSN19h
Evercore ISI Group Upgrades CRISPR Therapeutics (CRSP)
Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) ...
Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI
Evercore ISI analyst Liisa Bayko upgraded Crispr Therapeutics (CRSP) to Outperform from In Line with a price target of $99, up from $60.
PG&E price target lowered to $15 from $20 at Evercore ISI
Evercore ISI analyst Michael Lonegan lowered the firm’s price target on PG&E to $15 from $20 and keeps an In Line rating on the shares. The ...